(Q33383026)

English

A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Europe PubMed Central

A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

thrombocytopenia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Stephen R Foley

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kathryn Webert

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Donald M Arnold

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Gail A Rock

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

William F Clark

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

David M Sutton

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Members of the Canada Apheresis Group (CAG)

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kidney International. Supplement

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

112

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

S55-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19180138%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Chronic idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Current concepts in thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical practice. Thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab in patients with refractory thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.629

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33383026&oldid=1561114654"